Cangene (FRA:YGE) Asset Impairment Charge : €0.00 Mil (TTM As of Oct. 2013)

View and export this data going back to . Start your Free Trial

What is Cangene Asset Impairment Charge?

Cangene's Asset Impairment Charge for the three months ended in Oct. 2013 was €0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Oct. 2013 was €0.00 Mil.

Cangene Asset Impairment Charge Historical Data

The historical data trend for Cangene's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cangene Asset Impairment Charge Chart

Cangene Annual Data

Trend

Jul04

Jul05

Jul06

Jul07

Jul08

Jul09

Jul10

Jul11

Jul12

Jul13

Asset Impairment Charge

Get a 7-Day Free Trial

Cangene Quarterly Data
	Jan09	Apr09	Jul09	Oct09	Jan10	Apr10	Jul10	Oct10	Jan11	Apr11	Jul11	Oct11	Jan12	Apr12	Jul12	Oct12	Jan13	Apr13	Jul13	Oct13
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Cangene Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Oct. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Cangene Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Cangene's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Cangene (FRA:YGE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cangene Corporation (FRA:YGE) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cangene.com

Cangene Corporation is a fully integrated developer and manufacturer of immune therapeutics, primarily targeting infectious disease, hematology, transplantation and biodefense applications. The company manages its business and evaluate performance based on two operating segments: biopharmaceutical operations and contract services. Revenues are generated from product sales, and contract manufacturing and contract-R&D services.

Cangene (FRA:YGE) Headlines

No Headlines